Edition:
United States

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

9.22USD
28 Mar 2017
Change (% chg)

$-0.27 (-2.85%)
Prev Close
$9.49
Open
$9.48
Day's High
$9.48
Day's Low
$9.20
Volume
40,197
Avg. Vol
60,813
52-wk High
$15.48
52-wk Low
$7.41

Latest Key Developments (Source: Significant Developments)

Oncomed Pharmaceuticals Q4 loss per share $0.60
Wednesday, 8 Mar 2017 04:05pm EST 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.60 . Q4 revenue $6.2 million versus $6.8 million . Oncomed Pharmaceuticals Inc - Oncomed expects operating cash burn to be less than $100 million for full year 2017 . Oncomed Pharmaceuticals Inc - current cash is estimated to be sufficient to fund operations through Q3 of 2018 . Q4 earnings per share view $-0.68 -- Thomson Reuters I/B/E/S .Q4 revenue view $8.9 million -- Thomson Reuters I/B/E/S.  Full Article

OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab
Friday, 20 Jan 2017 08:30am EST 

OncoMed Pharmaceuticals Inc :OncoMed initiates enrollment of phase 1B clinical trial of Brontictuzumab for the treatment of metastatic colorectal cancer patients.  Full Article

OncoMed announces year-end cash balance and 2017 outlook
Thursday, 5 Jan 2017 08:30am EST 

Oncomed Pharmaceuticals Inc : OncoMed announces year-end cash balance and 2017 outlook . Expects 2017 operating cash burn to be less than $100 million, before considering potential milestones/opt-ins . "Phase 2 clinical trial results for demcizumab and tarextumab are anticipated in first half of year" . "Oncomed could receive more than $170 million in total 2017 partner opt-in payments" .Expects to file an IND in first half of 2017 for Oncomed's wholly owned GITRL-FC (OMP-336B11) trimer program.  Full Article

BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals - SEC filing
Friday, 26 Aug 2016 01:32pm EDT 

BVF Inc:BVF Inc reports 4.9 pct passive stake in Oncomed Pharmaceuticals as of Aug. 18, 2016 - SEC filing.  Full Article

Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals
Wednesday, 24 Aug 2016 06:23am EDT 

Oncomed Pharmaceuticals :Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing.  Full Article

OncoMed Pharmaceuticals prices public offering of common stock
Thursday, 18 Aug 2016 08:00am EDT 

OncoMed Pharmaceuticals Inc : OncoMed Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 5.50 million common shares priced at $10.00 per share.  Full Article

Oncomed Pharmaceuticals announces proposed public offering of common stock
Wednesday, 17 Aug 2016 04:07pm EDT 

Oncomed Pharmaceuticals Inc : Oncomed Pharmaceuticals announces proposed public offering of common stock .To use net proceeds from offering for general corporate purposes, increasing working capital, funding research development.  Full Article

Oncomed pharmaceuticals reports Q2 2016 financial results
Tuesday, 9 Aug 2016 04:05pm EDT 

Oncomed Pharmaceuticals Inc : Oncomed pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.91.  Full Article

OncoMed provides update on tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
Monday, 25 Jan 2016 07:30am EST 

OncoMed Pharmaceuticals Inc:Announces an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB).No unexpected safety findings emerged from its review.Says eighteen patients remain on study drug treatment (tarextumab or placebo) between 172 and 527 days.  Full Article

OncoMed completes enrollment of phase 2 alpine clinical trial of tarextumab in pancreatic cancer
Monday, 31 Aug 2015 08:30am EDT 

OncoMed:Says it has completed patient enrollment in its Phase 2 'ALPINE' clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of pancreatic cancer more than eight months ahead of schedule.Says the ALPINE study enrolled 177 patients with advanced pancreatic cancer who had not received prior treatment.Says enrollment in the randomized, double-blinded, multi-center clinical study began in July 2014.  Full Article

More From Around the Web

BRIEF-Oncomed Pharmaceuticals Q4 loss per share $0.60

* Oncomed Pharmaceuticals announces fourth quarter and full year 2016 financial results